Suven Life Sciences Limited
Masupirdine 50 mg
Agitation
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for Masupirdine 50 mg in Agitation are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05397639: Phase 3 trial, sponsor Suven Life Sciences Limited, drug Masupirdine 50 mg. Primary completion date 2026-12 (estimated).”